Current Report Filing (8-k)

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): December 2, 2015

EXACTECH, INC.

(Exact Name of Registrant as Specified in Its Charter)



Florida	0-28240	59-2603930
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(IRS Employer Identification No.)

2320 NW 66^th Court

Gainesville, Florida 32653

(Address of Principal Executive Office)

Registrant’s telephone number, including area code (352) 377-1140

(Former Name or Former Address, if Changed Since Last Report)

__________________________

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)


[ ]	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))


[ ]	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 8.01. Other Events.

On December 2, 2015, the board of directors of Exactech, Inc. (the “Company”) has authorized the company to buy back up to 1.0 million shares of Exactech stock over the next two years. A copy of a press release announcing the common stock repurchase authorization is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

Any repurchases will be made from time to time in open market transactions. Repurchases may be made at times under 10b5-1 plans, which would permit shares to be repurchased through pre-determined criteria when the Company would otherwise be prohibited from doing so under insider trading laws. The common stock repurchases will be at the discretion of management, dependent on market conditions, applicable securities laws and other factors. This share repurchase program does not obligate the Company to acquire any particular amount of common stock, and it may be suspended or discontinued at any time, subject to the requirements of the governing 10b5-1 plan.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.



Exhibit Number	Description
99.1	Press Release issued by the Company on December 7, 2015.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

EXACTECH, INC.



Date:	December 10, 2015	By:	/s/ Joel C. Phillips
			Joel C. Phillips
			Chief Financial Officer

EXHIBIT INDEX



Exhibit Number	Description
99.1	Press Release issued by the Company on December 7, 2015

EXHIBIT 99.1

Exactech Announces Stock Repurchase Authorization

Gainesville, Fla. - December 7, 2015 -- Exactech, Inc. (Nasdaq: EXAC), a developer and producer of bone and joint restoration products for hip, knee, shoulder and spine, announced today that its board of directors has authorized the company to buy back up to 1.0 million shares of Exactech stock over the next two years.

“Based on historical prices for Exactech stock, it is presently trading at a level which presents an attractive investment opportunity for the company itself,” said Chief Executive Officer David Petty. “We feel confident about the business prospects for our company as well as the likelihood of achieving these prospects. Economic and other market conditions, available funds and future capital requirements and alternatives available to Exactech, also led us to believe that it is in the best interests of the company and its shareholders for Exactech to undertake this repurchase to further strengthen our present and future financial position.”

About Exactech

Based in Gainesville, Fla., Exactech develops and markets orthopaedic implant devices, related surgical instruments and biologic materials and services to hospitals and physicians. The company manufactures many of its orthopaedic devices at its Gainesville facility. Exactech’s orthopaedic products are used in the restoration of bones and joints that have deteriorated as a result of injury or diseases such as arthritis. Exactech markets its products in the United States, in addition to more than 30 markets in Europe, Latin America, Asia and the Pacific. Additional information about Exactech, Inc. can be found at http://www.exac.com. Copies of Exactech’s press releases, SEC filings, current price quotes and other valuable information for investors may be found at http://www.exac.com and http://www.hawkassociates.com.

An investment profile on Exactech may be found at http://www.hawkassociates.com/profile/exac.cfm. To receive future releases in e-mail alerts, sign up at http://www.hawkassociates.com/about/alert.

This release contains various forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, which represent the company’s expectations or beliefs concerning future events of the company’s financial performance. These forward-looking statements are further qualified by important factors that could cause actual results to differ materially from those in the forward-looking statements. These factors include the effect of competitive pricing, the company’s dependence on the ability of third party manufacturers to produce components on a basis which is cost-effective to the company, market acceptance of the company’s products and the effects of government regulation. Results actually achieved may differ materially from expected results included in these statements.

Investor contacts Julie Marshall or Frank Hawkins

Jody Phillips Hawk Associates

Executive Vice President of Finance & 305-451-1888

Chief Financial Officer E-mail:EXAC@hawkassociates.com

352-377-1140

Media contact

Priscilla Bennett

Vice President, Corporate & Marketing Communication

352-377-1140

--MORE--

EXACTECH INC.

Page 1 of 2